{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:24:44Z","timestamp":1792013084252,"version":"4.4.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T00:00:00Z","timestamp":1728604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-74340-5","type":"journal-article","created":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T06:02:04Z","timestamp":1728626524000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Selective activation of PPAR\u03b1 by pemafibrate mitigates peritoneal inflammation and fibrosis through suppression of NLRP3 inflammasome and modulation of inflammation"],"prefix":"10.1038","volume":"14","author":[{"given":"Yutaka","family":"Shinkai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Ike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Osaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Ishiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Maeoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,11]]},"reference":[{"key":"74340_CR1","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/s41581-022-00623-7","volume":"18","author":"AK Bello","year":"2022","unstructured":"Bello, A. K. et al. Epidemiology of peritoneal dialysis outcomes. Nat. Rev. Nephrol. 18, 779\u2013793 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"74340_CR2","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1681\/ASN.2009070694","volume":"21","author":"O Devuyst","year":"2010","unstructured":"Devuyst, O., Margetts, P. J. & Topley, N. The pathophysiology of the peritoneal membrane. J. Am. Soc. Nephrol. 21, 1077\u20131085 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"74340_CR3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.kint.2016.03.040","volume":"90","author":"Q Zhou","year":"2016","unstructured":"Zhou, Q., Bajo, M. A., Del Peso, G., Yu, X. & Selgas, R. Preventing peritoneal membrane fibrosis in peritoneal dialysis patients. Kidney Int. 90, 515\u2013524 (2016).","journal-title":"Kidney Int."},{"issue":"Suppl 2","key":"74340_CR4","first-page":"S175","volume":"23","author":"Y Kawaguchi","year":"2003","unstructured":"Kawaguchi, Y. et al. Searching for the reasons for drop-out from peritoneal dialysis: A nationwide survey in Japan. Perit. Dial Int. 23 (Suppl 2), S175\u2013177 (2003).","journal-title":"Perit. Dial Int."},{"key":"74340_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10157-011-0471-8","volume":"15","author":"M Mizuno","year":"2011","unstructured":"Mizuno, M. et al. Peritonitis is still an important factor for withdrawal from peritoneal dialysis therapy in the Tokai area of Japan. Clin. Exp. Nephrol. 15, 727\u2013737 (2011).","journal-title":"Clin. Exp. Nephrol."},{"key":"74340_CR6","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3747\/pdi.2013.00074","volume":"34","author":"M Nakayama","year":"2014","unstructured":"Nakayama, M. et al. Encapsulating peritoneal sclerosis in the era of a multi-disciplinary approach based on biocompatible solutions: The NEXT-PD study. Perit. Dial Int. 34, 766\u2013774 (2014).","journal-title":"Perit. Dial Int."},{"key":"74340_CR7","doi-asserted-by":"publisher","first-page":"F999","DOI":"10.1152\/ajprenal.00012.2016","volume":"311","author":"J Perl","year":"2016","unstructured":"Perl, J. & Bargman, J. M. Peritoneal dialysis: From bench to bedside and bedside to bench. Am. J. Physiol. Ren. Physiol. 311, F999\u2013F1004 (2016).","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"74340_CR8","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.biocel.2016.04.016","volume":"77","author":"TA Morinelli","year":"2016","unstructured":"Morinelli, T. A., Luttrell, L. M., Strungs, E. G. & Ullian, M. E. Angiotensin II receptors and peritoneal dialysis-induced peritoneal fibrosis. Int. J. Biochem. Cell. Biol. 77, 240\u2013250 (2016).","journal-title":"Int. J. Biochem. Cell. Biol."},{"key":"74340_CR9","doi-asserted-by":"publisher","first-page":"607204","DOI":"10.3389\/fimmu.2021.607204","volume":"12","author":"M Terri","year":"2021","unstructured":"Terri, M. et al. Mechanisms of peritoneal fibrosis: Focus on Immune cells-peritoneal stroma interactions. Front. Immunol. 12, 607204 (2021).","journal-title":"Front. Immunol."},{"key":"74340_CR10","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.immuni.2013.10.022","volume":"40","author":"CA Fielding","year":"2014","unstructured":"Fielding, C. A. et al. Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 40, 40\u201350 (2014).","journal-title":"Immunity"},{"key":"74340_CR11","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/35013000","volume":"405","author":"S Kersten","year":"2000","unstructured":"Kersten, S., Desvergne, B. & Wahli, W. Roles of PPARs in health and disease. Nature 405, 421\u2013424 (2000).","journal-title":"Nature"},{"key":"74340_CR12","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1074\/jbc.273.10.5678","volume":"273","author":"T Aoyama","year":"1998","unstructured":"Aoyama, T. et al. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J. Biol. Chem. 273, 5678\u20135684 (1998).","journal-title":"J. Biol. Chem."},{"key":"74340_CR13","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1210\/er.2018-00064","volume":"39","author":"N Bougarne","year":"2018","unstructured":"Bougarne, N. et al. Molecular actions of PPAR\u03b1 in lipid metabolism and inflammation. Endocr. Rev. 39, 760\u2013802 (2018).","journal-title":"Endocr. Rev."},{"key":"74340_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1172\/JCI27989","volume":"116","author":"P Lefebvre","year":"2006","unstructured":"Lefebvre, P., Chinetti, G., Fruchart, J. C. & Staels, B. Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis. J. Clin. Invest. 116, 571\u2013580 (2006).","journal-title":"J. Clin. Invest."},{"key":"74340_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/384039a0","volume":"384","author":"PR Devchand","year":"1996","unstructured":"Devchand, P. R. et al. The PPARalpha-leukotriene B4 pathway to inflammation control. Nature 384, 39\u201343 (1996).","journal-title":"Nature"},{"key":"74340_CR16","doi-asserted-by":"publisher","first-page":"32048","DOI":"10.1074\/jbc.274.45.32048","volume":"274","author":"P Delerive","year":"1999","unstructured":"Delerive, P. et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J. Biol. Chem. 274, 32048\u201332054 (1999).","journal-title":"J. Biol. Chem."},{"key":"74340_CR17","doi-asserted-by":"publisher","first-page":"36703","DOI":"10.1074\/jbc.M004045200","volume":"275","author":"P Delerive","year":"2000","unstructured":"Delerive, P., Gervois, P., Fruchart, J. C. & Staels, B. Induction of IkappaBalpha expression as a mechanism contributing to the anti-inflammatory activities of peroxisome proliferator-activated receptor-alpha activators. J. Biol. Chem. 275, 36703\u201336707 (2000).","journal-title":"J. Biol. Chem."},{"key":"74340_CR18","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.atherosclerosis.2017.03.032","volume":"261","author":"H Arai","year":"2017","unstructured":"Arai, H. et al. Efficacy and safety of K-877, a novel selective peroxisome proliferator-activated receptor \u03b1 modulator (SPPARM\u03b1), in combination with statin treatment: Two randomised, double-blind, placebo-controlled clinical trials in patients with dyslipidaemia. Atherosclerosis 261, 144\u2013152 (2017).","journal-title":"Atherosclerosis"},{"key":"74340_CR19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","volume":"16","author":"JC Fruchart","year":"2017","unstructured":"Fruchart, J. C. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. Cardiovasc. Diabetol. 16, 124 (2017).","journal-title":"Cardiovasc. Diabetol."},{"key":"74340_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","volume":"12","author":"S Ishibashi","year":"2018","unstructured":"Ishibashi, S. et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J. Clin. Lipidol. 12, 173\u2013184 (2018).","journal-title":"J. Clin. Lipidol."},{"key":"74340_CR21","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1161\/HYPERTENSIONAHA.107.092403","volume":"50","author":"NK Lebrasseur","year":"2007","unstructured":"Lebrasseur, N. K. et al. Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension. Hypertension 50, 489\u2013496 (2007).","journal-title":"Hypertension"},{"key":"74340_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ejphar.2012.05.026","volume":"689","author":"M Samah","year":"2012","unstructured":"Samah, M., El-Aidy Ael, R., Tawfik, M. K. & Ewais, M. M. Evaluation of the antifibrotic effect of fenofibrate and rosiglitazone on bleomycin-induced pulmonary fibrosis in rats. Eur. J. Pharmacol. 689, 186\u2013193 (2012).","journal-title":"Eur. J. Pharmacol."},{"key":"74340_CR23","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/ki.2011.254","volume":"80","author":"P Boor","year":"2011","unstructured":"Boor, P. et al. The peroxisome proliferator-activated receptor-\u03b1 agonist, BAY PP1, attenuates renal fibrosis in rats. Kidney Int. 80, 1182\u20131197 (2011).","journal-title":"Kidney Int."},{"key":"74340_CR24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.bbrc.2004.09.110","volume":"324","author":"T Toyama","year":"2004","unstructured":"Toyama, T. et al. PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem. Biophys. Res. Commun. 324, 697\u2013704 (2004).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"74340_CR25","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nri3452","volume":"13","author":"E Latz","year":"2013","unstructured":"Latz, E., Xiao, T. S. & Stutz, A. Activation and regulation of the inflammasomes. Nat. Rev. Immunol. 13, 397\u2013411 (2013).","journal-title":"Nat. Rev. Immunol."},{"key":"74340_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","volume":"19","author":"KV Swanson","year":"2019","unstructured":"Swanson, K. V., Deng, M. & Ting, J. P. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. Nat. Rev. Immunol. 19, 477\u2013489 (2019).","journal-title":"Nat. Rev. Immunol."},{"key":"74340_CR27","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","volume":"140","author":"K Schroder","year":"2010","unstructured":"Schroder, K. & Tschopp, J. The inflammasomes. Cell 140, 821\u2013832 (2010).","journal-title":"Cell"},{"key":"74340_CR28","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1681\/ASN.2010020143","volume":"21","author":"A Vilaysane","year":"2010","unstructured":"Vilaysane, A. et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J. Am. Soc. Nephrol. 21, 1732\u20131744 (2010).","journal-title":"J. Am. Soc. Nephrol."},{"key":"74340_CR29","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/ki.2012.475","volume":"83","author":"Y Nishi","year":"2013","unstructured":"Nishi, Y. et al. Selective estrogen receptor modulation attenuates proteinuria-induced renal tubular damage by modulating mitochondrial oxidative status. Kidney Int. 83, 662\u2013673 (2013).","journal-title":"Kidney Int."},{"key":"74340_CR30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3389\/fimmu.2013.00050","volume":"4","author":"RW Grant","year":"2013","unstructured":"Grant, R. W. & Dixit, V. D. Mechanisms of disease: Inflammasome activation and the development of type 2 diabetes. Front. Immunol. 4, 50 (2013).","journal-title":"Front. Immunol."},{"key":"74340_CR31","doi-asserted-by":"publisher","first-page":"10363","DOI":"10.1038\/s41598-019-46504-1","volume":"9","author":"E Hishida","year":"2019","unstructured":"Hishida, E. et al. Crucial role of NLRP3 inflammasome in the development of peritoneal dialysis-related peritoneal fibrosis. Sci. Rep. 9, 10363 (2019).","journal-title":"Sci. Rep."},{"key":"74340_CR32","doi-asserted-by":"publisher","first-page":"e23129","DOI":"10.1096\/fj.202201777RRR","volume":"37","author":"H Kadoya","year":"2023","unstructured":"Kadoya, H. et al. Activation of the inflammasome drives peritoneal deterioration in a mouse model of peritoneal fibrosis. Faseb J. 37, e23129 (2023).","journal-title":"Faseb J."},{"key":"74340_CR33","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1038\/s41598-022-06542-8","volume":"12","author":"K Kanno","year":"2022","unstructured":"Kanno, K. et al. Pemafibrate suppresses NLRP3 inflammasome activation in the liver and heart in a novel mouse model of steatohepatitis-related cardiomyopathy. Sci. Rep. 12, 2996 (2022).","journal-title":"Sci. Rep."},{"key":"74340_CR34","doi-asserted-by":"publisher","first-page":"7818","DOI":"10.1038\/s41598-020-64902-8","volume":"10","author":"Y Sasaki","year":"2020","unstructured":"Sasaki, Y. et al. Pemafibrate, a selective PPAR\u03b1 modulator, prevents non-alcoholic steatohepatitis development without reducing the hepatic triglyceride content. Sci. Rep. 10, 7818 (2020).","journal-title":"Sci. Rep."},{"key":"74340_CR35","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1681\/ASN.2017070802","volume":"29","author":"KW Chung","year":"2018","unstructured":"Chung, K. W. et al. Impairment of PPAR\u03b1 and the fatty acid oxidation pathway aggravates renal fibrosis during aging. J. Am. Soc. Nephrol. 29, 1223\u20131237 (2018).","journal-title":"J. Am. Soc. Nephrol."},{"key":"74340_CR36","doi-asserted-by":"publisher","first-page":"E2048","DOI":"10.1073\/pnas.1415111112","volume":"112","author":"G Oruqaj","year":"2015","unstructured":"Oruqaj, G. et al. Compromised peroxisomes in idiopathic pulmonary fibrosis, a vicious cycle inducing a higher fibrotic response via TGF-\u03b2 signaling. Proc. Natl. Acad. Sci. U. S. A. 112, E2048\u20132057 (2015).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"74340_CR37","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1177\/089686080602600317","volume":"26","author":"I Hirahara","year":"2006","unstructured":"Hirahara, I. et al. Peritoneal injury by methylglyoxal in peritoneal dialysis. Perit. Dial Int. 26, 380\u2013392 (2006).","journal-title":"Perit. Dial Int."},{"key":"74340_CR38","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1093\/ndt\/gfn495","volume":"24","author":"I Hirahara","year":"2009","unstructured":"Hirahara, I., Ishibashi, Y., Kaname, S., Kusano, E. & Fujita, T. Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol. Dial Transpl. 24, 437\u2013447 (2009).","journal-title":"Nephrol. Dial Transpl."},{"key":"74340_CR39","doi-asserted-by":"publisher","first-page":"e22497","DOI":"10.1096\/fj.202200455RRR","volume":"36","author":"D Lee","year":"2022","unstructured":"Lee, D. et al. Retinal degeneration induced in a mouse model of ischemia-reperfusion injury and its management by pemafibrate treatment. Faseb J. 36, e22497 (2022).","journal-title":"Faseb J."},{"key":"74340_CR40","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/imm.12647","volume":"149","author":"S Oishi","year":"2016","unstructured":"Oishi, S. et al. M2 polarization of murine peritoneal macrophages induces regulatory cytokine production and suppresses T-cell proliferation. Immunology 149, 320\u2013328 (2016).","journal-title":"Immunology"},{"key":"74340_CR41","first-page":"6166","volume":"164","author":"CD Mills","year":"2000","unstructured":"Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J. & Hill, A. M. M-1\/M-2 macrophages and the Th1\/Th2 paradigm. J. Immunol. (Baltimore, Md.) 164, 6166\u20136173 (2000).","journal-title":"J. Immunol. (Baltimore, Md.)"},{"key":"74340_CR42","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","volume":"18","author":"LB Ivashkiv","year":"2018","unstructured":"Ivashkiv, L. B. IFN\u03b3: Signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat. Rev. Immunol. 18, 545\u2013558 (2018).","journal-title":"Nat. Rev. Immunol."},{"key":"74340_CR43","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3389\/fimmu.2017.01970","volume":"8","author":"M Metzemaekers","year":"2017","unstructured":"Metzemaekers, M., Vanheule, V., Janssens, R., Struyf, S. & Proost, P. Overview of the mechanisms that may contribute to the non-redundant activities of Interferon-Inducible CXC chemokine receptor 3 ligands. Front. Immunol. 8, 1970 (2017).","journal-title":"Front. Immunol."},{"key":"74340_CR44","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S1471-4906(01)02118-4","volume":"23","author":"CV Ramana","year":"2002","unstructured":"Ramana, C. V., Gil, M. P., Schreiber, R. D. & Stark, G. R. Stat1-dependent and -independent pathways in IFN-gamma-dependent signaling. Trends Immunol. 23, 96\u2013101 (2002).","journal-title":"Trends Immunol."},{"key":"74340_CR45","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F Martinon","year":"2002","unstructured":"Martinon, F., Burns, K. & Tschopp, J. The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol. Cell. 10, 417\u2013426 (2002).","journal-title":"Mol. Cell."},{"key":"74340_CR46","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1146\/annurev.immunol.021908.132715","volume":"27","author":"F Martinon","year":"2009","unstructured":"Martinon, F., Mayor, A. & Tschopp, J. The inflammasomes: Guardians of the body. Annu. Rev. Immunol. 27, 229\u2013265 (2009).","journal-title":"Annu. Rev. Immunol."},{"key":"74340_CR47","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/21505594.2022.2040188","volume":"13","author":"P Wan","year":"2022","unstructured":"Wan, P. et al. AP-1 signaling pathway promotes pro-IL-1\u03b2 transcription to facilitate NLRP3 inflammasome activation upon influenza a virus infection. Virulence 13, 502\u2013513 (2022).","journal-title":"Virulence"},{"key":"74340_CR48","doi-asserted-by":"crossref","unstructured":"Yang, A. H., Chen, J. Y. & Lin, J. K. Myofibroblastic conversion of mesothelial cells. Kidney Int. 63 (2003).","DOI":"10.1046\/j.1523-1755.2003.00861.x"},{"key":"74340_CR49","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.jacc.2003.11.043","volume":"43","author":"T Ogata","year":"2004","unstructured":"Ogata, T. et al. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J. Am. Coll. Cardiol. 43, 1481\u20131488 (2004).","journal-title":"J. Am. Coll. Cardiol."},{"key":"74340_CR50","doi-asserted-by":"publisher","first-page":"108728","DOI":"10.1016\/j.intimp.2022.108728","volume":"108","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Pemafibrate attenuates pulmonary fibrosis by inhibiting myofibroblast differentiation. Int. Immunopharmacol. 108, 108728 (2022).","journal-title":"Int. Immunopharmacol."},{"key":"74340_CR51","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/31701","volume":"393","author":"B Staels","year":"1998","unstructured":"Staels, B. et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 393, 790\u2013793 (1998).","journal-title":"Nature"},{"key":"74340_CR52","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/00041433-199904000-00009","volume":"10","author":"I Pineda Torra","year":"1999","unstructured":"Pineda Torra, I., Gervois, P. & Staels, B. Peroxisome proliferator-activated receptor alpha in metabolic disease, inflammation, atherosclerosis and aging. Curr. Opin. Lipidol. 10, 151\u2013159 (1999).","journal-title":"Curr. Opin. Lipidol."},{"key":"74340_CR53","doi-asserted-by":"publisher","first-page":"3405","DOI":"10.1016\/j.yexcr.2008.09.002","volume":"314","author":"IJ Souissi","year":"2008","unstructured":"Souissi, I. J., Billiet, L., Cuaz-P\u00e9rolin, C., Slimane, M. N. & Rouis, M. Matrix metalloproteinase-12 gene regulation by a PPAR alpha agonist in human monocyte-derived macrophages. Exp. Cell. Res. 314, 3405\u20133414 (2008).","journal-title":"Exp. Cell. Res."},{"key":"74340_CR54","doi-asserted-by":"publisher","first-page":"34611","DOI":"10.1038\/srep34611","volume":"6","author":"L Yang","year":"2016","unstructured":"Yang, L. et al. Oleoylethanolamide exerts anti-inflammatory effects on LPS-induced THP-1 cells by enhancing PPAR\u03b1 signaling and inhibiting the NF-\u03baB and ERK1\/2\/AP-1\/STAT3 pathways. Sci. Rep. 6, 34611 (2016).","journal-title":"Sci. Rep."},{"key":"74340_CR55","doi-asserted-by":"crossref","unstructured":"Grabacka, M., Pierzchalska, M., P\u0142onka, P. M. & Pierzchalski, P. The role of PPAR Alpha in the modulation of Innate Immunity. Int. J. Mol. Sci. 22 (2021).","DOI":"10.3390\/ijms221910545"},{"key":"74340_CR56","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1677\/joe.0.1690453","volume":"169","author":"P Delerive","year":"2001","unstructured":"Delerive, P., Fruchart, J. C. & Staels, B. Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 169, 453\u2013459 (2001).","journal-title":"J. Endocrinol."},{"key":"74340_CR57","doi-asserted-by":"publisher","first-page":"6115","DOI":"10.1038\/ncomms7115","volume":"6","author":"CS Yang","year":"2015","unstructured":"Yang, C. S. et al. Small heterodimer partner interacts with NLRP3 and negatively regulates activation of the NLRP3 inflammasome. Nat. Commun. 6, 6115 (2015).","journal-title":"Nat. Commun."},{"key":"74340_CR58","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nri978","volume":"3","author":"S Gordon","year":"2003","unstructured":"Gordon, S. Alternative activation of macrophages. Nat. Rev. Immunol. 3, 23\u201335 (2003).","journal-title":"Nat. Rev. Immunol."},{"key":"74340_CR59","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13287-023-03350-3","volume":"14","author":"N Ishiuchi","year":"2023","unstructured":"Ishiuchi, N. et al. Comparison of therapeutic effects of mesenchymal stem cells derived from superficial and deep subcutaneous adipose tissues. Stem Cell. Res. Ther. 14, 121 (2023).","journal-title":"Stem Cell. Res. Ther."},{"key":"74340_CR60","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s13287-021-02548-7","volume":"12","author":"N Ishiuchi","year":"2021","unstructured":"Ishiuchi, N. et al. Serum-free medium and hypoxic preconditioning synergistically enhance the therapeutic effects of mesenchymal stem cells on experimental renal fibrosis. Stem Cell. Res. Ther. 12, 472 (2021).","journal-title":"Stem Cell. Res. Ther."},{"key":"74340_CR61","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/ATVBAHA.107.158998","volume":"28","author":"E Rigamonti","year":"2008","unstructured":"Rigamonti, E., Chinetti-Gbaguidi, G. & Staels, B. Regulation of macrophage functions by PPAR-alpha, PPAR-gamma, and LXRs in mice and men. Arterioscler. Thromb. Vasc Biol. 28, 1050\u20131059 (2008).","journal-title":"Arterioscler. Thromb. Vasc Biol."},{"key":"74340_CR62","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.bbadis.2014.12.019","volume":"1852","author":"F Penas","year":"2015","unstructured":"Penas, F. et al. Treatment in vitro with PPAR\u03b1 and PPAR\u03b3 ligands drives M1-to-M2 polarization of macrophages from T. Cruzi-infected mice. Biochim. Biophys. Acta 1852, 893\u2013904 (2015).","journal-title":"Biochim. Biophys. Acta"},{"key":"74340_CR63","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41581-019-0110-2","volume":"15","author":"PM Tang","year":"2019","unstructured":"Tang, P. M., Nikolic-Paterson, D. J. & Lan, H. Y. Macrophages: Versatile players in renal inflammation and fibrosis. Nat. Rev. Nephrol. 15, 144\u2013158 (2019).","journal-title":"Nat. Rev. Nephrol."},{"key":"74340_CR64","doi-asserted-by":"publisher","first-page":"e0173706","DOI":"10.1371\/journal.pone.0173706","volume":"12","author":"K Maeda","year":"2017","unstructured":"Maeda, K. et al. Inhibition of H3K9 methyltransferase G9a ameliorates methylglyoxal-induced peritoneal fibrosis. PLoS ONE 12, e0173706 (2017).","journal-title":"PLoS ONE"},{"key":"74340_CR65","doi-asserted-by":"publisher","first-page":"e0196844","DOI":"10.1371\/journal.pone.0196844","volume":"13","author":"R Tamura","year":"2018","unstructured":"Tamura, R. et al. Inhibition of the H3K4 methyltransferase SET7\/9 ameliorates peritoneal fibrosis. PLoS ONE 13, e0196844 (2018).","journal-title":"PLoS ONE"},{"key":"74340_CR66","doi-asserted-by":"crossref","unstructured":"Murakami, K. et al. Selective PPAR\u03b1 modulator pemafibrate and sodium-glucose cotransporter 2 inhibitor tofogliflozin combination treatment improved histopathology in experimental mice model of non-alcoholic steatohepatitis. Cells 11 (2022).","DOI":"10.3390\/cells11040720"},{"key":"74340_CR67","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1681\/ASN.2020071010","volume":"32","author":"K Sasaki","year":"2021","unstructured":"Sasaki, K. et al. Deletion of Myeloid Interferon Regulatory Factor 4 (Irf4) in mouse model protects against kidney fibrosis after ischemic Injury by decreased macrophage recruitment and activation. J. Am. Soc. Nephrol. 32, 1037\u20131052 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"74340_CR68","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/ki.2013.81","volume":"84","author":"T Ueno","year":"2013","unstructured":"Ueno, T. et al. Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-\u03b21 signaling. Kidney Int. 84, 297\u2013307 (2013).","journal-title":"Kidney Int."},{"key":"74340_CR69","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1038\/ki.1990.150","volume":"37","author":"E Stylianou","year":"1990","unstructured":"Stylianou, E., Jenner, L. A., Davies, M., Coles, G. A. & Williams, J. D. Isolation, culture and characterization of human peritoneal mesothelial cells. Kidney Int. 37, 1563\u20131570 (1990).","journal-title":"Kidney Int."},{"key":"74340_CR70","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.kint.2023.08.010","volume":"104","author":"T Ishimura","year":"2023","unstructured":"Ishimura, T. et al. Matrix metalloproteinase-10 deficiency has protective effects against peritoneal inflammation and fibrosis via transcription factor NF\u03ba\u0392 pathway inhibition. Kidney Int. 104, 929\u2013942 (2023).","journal-title":"Kidney Int."},{"key":"74340_CR71","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1681\/ASN.2014090850","volume":"27","author":"K Sasaki","year":"2016","unstructured":"Sasaki, K. et al. Inhibition of SET domain-containing lysine methyltransferase 7\/9 ameliorates renal fibrosis. J. Am. Soc. Nephrol. 27, 203\u2013215 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"74340_CR72","doi-asserted-by":"crossref","unstructured":"Osaki, Y. et al. Blocking cell cycle progression through CDK4\/6 protects against chronic kidney disease. JCI Insight 7 (2022).","DOI":"10.1172\/jci.insight.158754"},{"key":"74340_CR73","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1161\/HYPERTENSIONAHA.122.19159","volume":"79","author":"Y Maeoka","year":"2022","unstructured":"Maeoka, Y. et al. Mineralocorticoid receptor antagonists cause natriuresis in the absence of aldosterone. Hypertension 79, 1423\u20131434 (2022).","journal-title":"Hypertension"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74340-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74340-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74340-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T10:05:20Z","timestamp":1728900320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-74340-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,11]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["74340"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-74340-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4003336\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,11]]},"assertion":[{"value":"1 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23816"}}